Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites

TitreTransjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites
Type de publicationArticle de revue
AuteurBureau, Christophe, Thabut, Dominique, Oberti, Frédéric , Dharancy, Sébastien, Carbonell, Nicolas, Bouvier, Antoine , Mathurin, Philippe, Otal, Philippe, Cabarrou, Pauline, Péron, Jean-Marie, Vinel, Jean-Pierre
TypeArticle scientifique dans une revue à comité de lecture
DateJanvier 2017
Titre de la revueGastroenterology
Mots-clésAlbumins, Ascites, Female, Hepatic Encephalopathy, Hospitalization, Humans, Hypertension, Portal, Liver Cirrhosis, Liver Transplantation, Male, Middle Aged, Paracentesis, Polytetrafluoroethylene, Portasystemic Shunt, Transjugular Intrahepatic, Prospective Studies, Recurrence, Severity of Illness Index, Stents, Survival rate, Ultrasonography, Doppler
Résumé en anglais

BACKGROUND & AIMS: There is controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrhosis and refractory ascites. The high rate of shunt dysfunction with the use of uncovered stents counteracts the benefits of TIPS. We performed a randomized controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in these patients.

METHODS: We performed a prospective study of 62 patients with cirrhosis and at least 2 large-volume paracenteses within a period of at least 3 weeks; the study was performed at 4 tertiary care centers in France from August 2005 through December 2012. Patients were randomly assigned to groups that received covered TIPS (n = 29) or large-volume paracenteses and albumin as necessary (LVP+A, n = 33). All patients maintained a low-salt diet and were examined at 1 month after the procedure then every 3 months until 1 year. At each visit, liver disease-related complications, treatment modifications, and clinical and biochemical variables needed to calculate Child-Pugh and Model for End-Stage Liver Disease scores were recorded. Doppler ultrasonography was performed at the start of the study and then at 6 and 12 months after the procedure. The primary study end point was survival without a liver transplant for 1 year after the procedure.

RESULTS: A higher proportion of patients in the TIPS group (93%) met the primary end point than in the LVP+A group (52%) (P = .003). The total number of paracenteses was 32 in the TIPS group vs 320 in the LVP+A group. Higher proportions of patients in the LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01) or hernia-related complications (18% vs 0%; P = .01) than in the TIPS group. Patients in LVP+A group had twice as many days of hospitalization (35 days) as the TIPS group (17 days) (P = .04). The 1-year probability of remaining free of encephalopathy was 65% for each group.

CONCLUSIONS: In a randomized trial, we found covered stents for TIPS to increase the proportion of patients with cirrhosis and recurrent ascites who survive transplantation-free for 1 year, compared with patients given repeated LVP+A. These findings support TIPS as the first-line intervention in such patients. ID: NCT00222014.

URL de la notice
Lien vers le document

Autre titreGastroenterology
Identifiant (ID) PubMed27663604